Hubbry Logo
N-EthylpentyloneN-EthylpentyloneMain
Open search
N-Ethylpentylone
Community hub
N-Ethylpentylone
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
N-Ethylpentylone
N-Ethylpentylone
N-Ethylpentylone
View on Wikipedia
from Wikipedia
N-Ethylpentylone
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H19NO3
Molar mass249.310 g·mol−1
3D model (JSmol)
  • CCNC(CCC)C(=O)c2ccc1OCOc1c2
  • InChI=1S/C14H19NO3/c1-3-5-11(15-4-2)14(16)10-6-7-12-13(8-10)18-9-17-12/h6-8,11,15H,3-5,9H2,1-2H3
  • Key:VERDHJIMZYXGIW-UHFFFAOYSA-N

N-Ethylpentylone (β-keto-ethylbenzodioxolylpentanamine, βk-ethyl-K, βk-EBDP, ephylone) is a substituted cathinone and stimulant drug which was developed in the 1960s.[2][3]

It has been reported as a novel designer drug in several countries including the United Kingdom,[4] South Africa,[5] New Zealand,[6] the United States,[7] and Australia.[8] In 2018, N-ethylpentylone was the most common drug of the cathinone class to be identified in Drug Enforcement Administration seizures.[9]

Adverse effects

[edit]

N-Ethylpentylone has been reported to cause lethal heart palpitations and hallucinations.[10] It has been linked to a number of overdose deaths[11][7] and hospitalisations,[12][13] and has increasingly been mis-sold as MDMA.[14]

Pharmacology

[edit]

N-Ethylpentylone is primarily a mixed norepinephrine reuptake inhibitor and dopamine reuptake inhibitor. It binds to transporters with IC50 values of 37 nM (dopamine transporter), 105 nM (norepinephrine transporter) and 383 nM (serotonin transporter).[15] The methylenedioxy ring-substitution provides a higher potency at inhibiting serotonin reuptake than its analogue N-ethylpentedrone.[16] N-Ethylpentylone is also a low-potency serotonin 5-HT2A receptor agonist, with an EC50Tooltip half-maximal effective concentration of 5,200 nM.[17]

In vivo studies in mice demonstrated that acute intraperitoneal administration of N-ethylpentylone induced an increase in locomotor activity, anxiolytic effects but also an aggressive behaviour as well as social exploration deficits. Repeated exposure to N-ethylpentylone induced hyperthermia, anorexia and rewarding effects. During withdrawal after repeated administration, depression-like symptoms, hyperlocomotion, and a decrease of social exploration were observed.[16][18]

Society and culture

[edit]
[edit]
  • In the United States, N-ethylpentylone is a Schedule I controlled substance since June 2018.[19]
  • In Taiwan, N-ethylpentylone is a controlled substance under Taiwan's Controlled Drugs Act since Dec 2017.[20]
  • In the Netherlands it has been added to the Opium Law on July 1 2025.[21]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

N-Ethylpentylone

View on Grokipedia
from Grokipedia
-Ethylpentylone, chemically known as 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one and also referred to as ephylone, is a synthetic that functions as a potent by inhibiting the of and norepinephrine in the . This compound produces pharmacological effects similar to and other Schedule I phenethylamines, including , increased energy, and heightened alertness, but with significant risks of , agitation, , and hallucinations. Emerging as a psychoactive substance around 2016, N-ethylpentylone rapidly gained traction in illicit markets as a substitute for controlled cathinones like , often misrepresented or sold under misleading labels in recreational contexts. Its abuse has been linked to numerous cases of and fatal overdoses, with postmortem analyses confirming its presence in individuals exhibiting severe cardiovascular and neurological symptoms prior to death. Empirical pharmacokinetic studies in rodents demonstrate rapid brain penetration and elevation of extracellular and serotonin levels in the , contributing to its reinforcing properties and potential for . Due to its high potential for abuse, lack of accepted medical use, and absence of safety under medical supervision, the U.S. temporarily placed N-ethylpentylone into Schedule I of the in 2018, followed by permanent scheduling in 2021. Animal behavioral assays indicate dose-dependent increases in locomotor activity and reductions in anxiety-like behaviors at lower doses, but repeated administration leads to neurochemical adaptations suggestive of tolerance and dependence. These characteristics underscore its role in the ongoing challenge of synthetic cathinones as threats, with forensic data highlighting its prevalence in polydrug intoxications.

Chemical Properties

Structure and Classification

N-Ethylpentylone possesses the molecular formula C14_{14}H19_{19}NO3_{3} and has a molar mass of 249.31 g/mol. Its systematic IUPAC name is 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one. The core structure consists of a 1,3-benzodioxole ring attached to a pentan-1-one chain, with an ethylamino group at the 2-position, making it a β-keto amphetamine analog. As a , N-ethylpentylone belongs to the chemical class, characterized by the presence of a β-ketone functionality adjacent to the backbone. This classification aligns it with other synthetic s, which are derivatives of the naturally occurring found in the plant. Structurally, it exhibits close resemblance to and , sharing the benzodioxole moiety and extended alkyl chain on the carbonyl side, but differentiated by the N-ethyl substitution on the amine nitrogen, in contrast to the N-methyl group in and . In forensic contexts, N-ethylpentylone typically appears as a white powder. Identification relies on analytical methods including gas chromatography-mass spectrometry (GC-MS) for separation and mass spectral matching, as well as nuclear magnetic resonance (NMR) spectroscopy for structural confirmation. These techniques enable differentiation from structural isomers and analogs in seized materials.

Synthesis and Precursors


N-Ethylpentylone is synthesized through a standard two-step process employed for many synthetic cathinones, involving α-bromination of the precursor ketone 1-(1,3-benzodioxol-5-yl)pentan-1-one to form the α-bromoketone intermediate, followed by nucleophilic substitution with ethylamine to introduce the ethylamino group. This route, originally developed in the 1960s for similar stimulants, relies on the aryl pentanone as the key starting material, which can be prepared from piperonal derivatives and butyl organometallics or nitriles.
Clandestine production adapts these methods but often lacks rigorous controls, leading to impurities such as unreacted bromoketones or diastereomeric byproducts, which contribute to variable purity in seized samples. Ethylamine and bromine serve as critical reagents, with the benzodioxole-containing ketone representing a watched precursor in forensic contexts due to its role in multiple cathinone analogs.
The shared synthetic pathways with structural analogs, such as pentylone (substituting methylamine for ethylamine), pose analytical challenges in distinguishing N-ethylpentylone from related compounds during precursor-based identification, necessitating advanced spectroscopic confirmation. While routes akin to those for MDMA analogs from safrole derivatives may indirectly supply the benzodioxole scaffold, direct cathinone synthesis emphasizes the alpha-functionalization of the pentanone precursor.

Pharmacology

Mechanism of Action

N-Ethylpentylone functions primarily as an inhibitor of monoamine transporters, blocking the reuptake of , norepinephrine, and serotonin into presynaptic neurons, which elevates their extracellular concentrations in the . This mechanism underlies its effects by enhancing monoaminergic , particularly in and noradrenergic pathways. Unlike substrate-type releasers such as , N-ethylpentylone exhibits no significant transporter-mediated release of monoamines, acting instead as a pure uptake blocker similar to , though with greater potency at the (DAT). In vitro studies report IC50 values of 37 nM at DAT, 105 nM at the (NET), and 383 nM at the (SERT), demonstrating approximately 10-fold selectivity for DAT over SERT. This DAT-preferring profile contributes to its pronounced psychomotor stimulation, with comparatively weaker serotonergic activity distinguishing it from entactogenic cathinones like that show balanced or SERT-dominant inhibition. The absence of vesicular monoamine transporter 2 ()-mediated release further limits its action to synaptic blockade, potentially prolonging effects through sustained elevation of levels without rapid depletion of vesicular stores.

Pharmacokinetics and Metabolism

N-Ethylpentylone undergoes rapid absorption and distribution following administration, with peak concentrations in the achieved approximately 40 minutes after at doses of 20 or 50 mg/kg. Approximately 4% of plasma levels distribute to this region, indicating efficient blood-brain barrier penetration and potential for homogeneous distribution exceeding 90% of plasma exposure. In intoxication cases, concentrations range from 12 to 1,200 ng/mL (mean 313 ng/mL), with oral fluid levels up to 1,377 ng/mL, reflecting influenced by administration route—oral absorption typically yields onset within 30-60 minutes based on analogs, while may accelerate this. Elimination in rat is approximately 61 minutes, correlating with psychostimulant effects diminishing after 60 minutes and full return to baseline within 3-4 hours in self-administration models. Metabolism is predominantly hepatic, as demonstrated in liver microsome incubations producing four phase I metabolites detectable in authentic and oral fluid specimens from users. The primary metabolite arises from β-ketone reduction to a hydroxyl group, serving as a unique for forensic confirmation due to its specificity to N-ethylpentylone. occurs mainly via , with these metabolites extending post-administration detectability windows in toxicological analyses, though individual variability in enzyme activity—common among cathinones—can alter clearance rates.

History

Early Development

N-Ethylpentylone, also known as N-ethylnorpentylone or ephylone, was first synthesized and described in the 1960s by pharmaceutical chemists at as part of efforts to develop synthetic analogs of , the primary psychoactive derived from the plant (Catha edulis). This focused on modifying the beta-keto scaffold to explore potential properties, building on early investigations into cathinone's structure-activity relationships (SAR) for pharmaceutical applications such as appetite suppression or central nervous system stimulation. Early work positioned N-ethylpentylone as a structural variant with an N-ethyl substitution and a on the core framework, extending from simpler analogs like those studied in the mid-20th century for their amphetamine-like effects. However, archival records indicate no progression to advanced preclinical or clinical trials, likely due to unfavorable pharmacokinetic profiles or toxicity concerns common in substituted cathinones, which often exhibited limited therapeutic windows compared to established stimulants. No patents specifically advancing N-ethylpentylone for medical use have been identified from this era, reflecting its status as one of many exploratory compounds in broader analog programs that prioritized more viable candidates.

Emergence as a Designer Drug

N-Ethylpentylone emerged in the United States illicit market around 2014, following the scheduling of other popular synthetic cathinones, as vendors sought alternatives to maintain supply amid regulatory crackdowns on novel psychoactive substances (NPS). It was initially detected in recreational samples and marketed online under aliases such as "bk-EBDP" or as an ethyl analog of , exploiting structural similarities to evade bans on related β-keto analogs while positioning it as a "legal high" substitute for stimulants like . U.S. Customs and Border Protection reported the first seizures of N-ethylpentylone in 2016, coinciding with its broader appearance in domestic encounters, often misrepresented as or other entactogens in powder or pill form. Distribution primarily occurred through vendors and online platforms, including those catering to NPS enthusiasts, which facilitated rapid dissemination but introduced variability due to inconsistent purity and adulteration in products. By 2018, N-ethylpentylone surged in prevalence, accounting for 79% of synthetic cathinones identified in local seizures at its peak, reflecting its role as a direct substitute for scheduled compounds amid the ongoing "legal high" market dynamics that prioritized unscheduled structural variants. This rapid rise underscored the adaptive strategies of illicit suppliers, who leveraged minor chemical modifications to prolong market viability before eventual regulatory response.

Effects on Users

Subjective and Desired Effects

Users seek N-ethylpentylone for its reported capacity to induce , heightened , increased sociability, and elevated levels, effects likened by some to those of at lower doses. These subjective outcomes are frequently described in user accounts as promoting enhanced mood, focus, and interpersonal connectedness, positioning the substance as an alternative in recreational settings like raves where MDMA-like experiences are desired. However, such reports derive largely from anecdotal sources including drug surveys and online forums, lacking robust empirical validation from controlled human trials. At doses around 20-40 mg, self-reports indicate a progression from initial to sensory enhancement and mild empathogenic qualities, with peak effects sustaining for 3-6 hours before gradual abatement. Higher doses may yield intensified and subtle visual alterations, though these remain dose-dependent and variably reported across users. The appeal as a "legal" substitute stems from its emergence in markets evading initial controls, often misrepresented as ecstasy, though actual experiences emphasize over purely entactogenic profiles. These accounts, while consistent in highlighting sought-after positives, are constrained by self-selection bias and absence of standardized dosing or controls in available data.

Acute Adverse Effects

Acute intoxication with N-ethylpentylone elicits sympathomimetic symptoms such as , , , agitation, and , resulting from excessive noradrenergic and dose-dependent stimulation of the central and peripheral nervous systems. Other somatic manifestations include , , diaphoresis, and , which intensify with increasing doses and correlate with plasma concentrations observed in clinical presentations. Psychological effects encompass anxiety, paranoia, confusion, disorientation, and psychomotor agitation, emerging shortly after ingestion and persisting in proportion to dose and duration of exposure. Visual hallucinations occur less frequently than with pure dopaminergic stimulants like methamphetamine, appearing in approximately 4 out of 11 documented cases of acute toxicity, often alongside agitation and acidosis. When adulterated into polydrug products such as counterfeit ecstasy or , N-ethylpentylone exacerbates risks through synergistic sympathomimetic interactions, leading to heightened agitation, , and beyond isolated use. These amplified effects stem from combined monoamine inhibition, with evidenced in intoxication series where co-ingestants correlated with more severe initial presentations.

Scientific Research

Animal Studies

Preclinical studies in demonstrate that N-ethylpentylone produces stimulant-like behavioral effects, including dose-dependent locomotor stimulation. In Sprague-Dawley rats, intraperitoneal doses of 5–50 mg/kg elicited an inverted U-shaped increase in locomotor activity, peaking at 20 mg/kg with distances up to 18 times greater than saline controls, though repeated administration did not induce sensitization upon re-challenge after withdrawal. In mice, acute administration yielded an ED₅₀ of 0.73 mg/kg for locomotor activation, with effects onsetting within 10 minutes and lasting 30–130 minutes at 89–93% maximum possible effect, comparable to and other cathinones. Reinforcing properties are evidenced by self-administration and paradigms. Male Sprague-Dawley rats self-administered N-ethylpentylone (0.1 mg/kg/infusion) under a fixed-ratio 1 , showing inverted U-shaped dose-response curves and an essential value of 5.21 in analysis, lower than (7.93) but indicative of significant relative to non-contingent saline. In young CD1 mice, N-ethylpentylone established at doses like 10 mg/kg, with males exhibiting greater resistance to (requiring over 31 sessions) and reinstatement at lower priming doses (0.5 mg/kg) than females (5 mg/kg); self-administration acquisition was higher in females at 0.75 mg/kg (89% vs. 31% in males). Discriminative stimulus effects in rats fully substituted for (ED₅₀ 1.65 mg/kg) and (ED₅₀ 1.98 mg/kg), aligning with Schedule I cathinones and supporting high abuse liability. Physiological responses include , particularly with repeated dosing. In mice administered 10 mg/kg intraperitoneally twice daily for 5 days, peaked on treatment days 2–4, with males showing stronger and more prolonged elevations than females. Acute high doses in rats (50 mg/kg) suppressed locomotion without reported s, though broader data suggest seizure risk at extreme exposures. assays post-repeated dosing revealed transient decreases in striatal and prefrontal serotonin and noradrenaline (at 72 hours, normalizing by 21 days) alongside persistent ΔFosB accumulation in , signaling neuroadaptations linked to dependence rather than overt long-term . Specific long-term studies for N-ethylpentylone remain limited.

Human Case Reports and Toxicology

Human case reports of N-ethylpentylone intoxication have documented acute presentations including agitation, , , hallucinations, seizures, , and multi-organ failure, often requiring intervention. In one series of clinical cases from 2018, patients exhibited symptoms such as , altered mental status, and , with blood concentrations ranging from 7 to 170 ng/mL confirmed via liquid chromatography-tandem (LC-MS/MS). These non-fatal intoxications typically involved co-ingestion of other substances, complicating attribution but correlating elevated N-ethylpentylone levels with sympathomimetic . Toxicological analyses in verified incidents employ validated methods like ultra-high-performance LC-MS/MS for quantification in , , and postmortem tissues, enabling detection limits as low as 1-5 ng/mL and distinguishing N-ethylpentylone from structural analogs. Non-fatal concentrations generally fall below 200 ng/mL, associating with intoxication severity, while postmortem levels in fatalities range from 170 to 1300 ng/mL, often alongside or other novel psychoactive substances (NPS). Emergency presentations since 2018 have included with creatine kinase elevations exceeding 10,000 U/L, , , and renal injury, as seen in a 21-year-old male who progressed to despite supportive care. Epidemiological data indicate rising detections in NPS screening programs, with over 17 reported clinical admissions, impaired driving, or death cases by 2019, frequently involving substances misrepresented as due to similar marketed effects and . Co-factors such as polydrug use amplify risks, with present in multiple instances at 0.6-3.6 g/L, contributing to atop N-ethylpentylone's monoamine inhibition. Confirmed cases underscore the need for targeted GC-MS or LC-MS confirmation to avoid misidentification in routine workflows.

Toxicity and Overdose

Physiological Mechanisms of Harm

N-Ethylpentylone inhibits the (DAT) and (NET) with high potency, elevating extracellular and norepinephrine levels and thereby inducing sympathetic overstimulation. This mechanism drives cardiovascular toxicity through alpha- and beta-adrenergic receptor agonism, manifesting as acute , , and potential arrhythmias or myocardial ischemia from sustained and increased myocardial oxygen demand. Although N-ethylpentylone exhibits lower affinity for the (SERT) compared to DAT and NET—typically 8- to 10-fold selectivity for dopamine over serotonin uptake inhibition—its structural similarity to methylenedioxy-containing cathinones like can still elevate serotonergic activity, raising the risk of via excess neurotransmitter accumulation, particularly under conditions of high dosing or concurrent serotonergic agents. Hyperthermic crises stem from disrupted hypothalamic thermoregulatory pathways, where monoamine excess impairs heat dissipation and promotes , compounded by user behaviors such as prolonged physical exertion in overheated environments. This leads to elevated core body temperatures that trigger systemic , mitochondrial dysfunction, and protein misfolding, amplifying downstream cellular injury independent of direct receptor effects. Synthetic cathinones like N-ethylpentylone, akin to analogs, further hinder peripheral and sweating responses, creating a feedback loop of escalating metabolic heat production. Renal toxicity arises primarily through , induced by intense , seizures, and ischemic muscle damage from norepinephrine-mediated , resulting in efflux that precipitates and glomerular filtration impairment. Hepatic stress involves hypoxic injury from and reduced , alongside potential oxidative burden from unmetabolized parent compound or phase I metabolites processed via enzymes, as inferred from autopsy-linked multi-organ failure patterns. , secondary to and antidiuretic hormone dysregulation akin to other sympathomimetics, exacerbates both renal hypoperfusion and hepatic concentration.

Documented Fatalities and Incidence

By 2018, the (DEA) had documented approximately 151 overdose deaths associated with N-ethylpentylone abuse in the , spanning from 2014 onward, with many cases involving polydrug use including other synthetic cathinones or depressants. Subsequent DEA assessments reported around 154 such deaths through 2018, emphasizing that attribution relied on postmortem confirming N-ethylpentylone presence, though causal roles were complicated by co-ingestants like or opioids in a majority of instances. Individual case reports illustrate toxicological findings in fatalities. For example, a 2019 Polish case involved a fatal intoxication with N-ethylpentylone at 10.6 μg/mL in peripheral blood and 17.6 μg/mL in heart blood, where the substance was deemed the primary cause amid signs of cardiovascular collapse. In cases, postmortem peripheral blood concentrations ranged from 121 ng/mL to 953 ng/mL, often presenting with or agitation as terminal events prior to cardiorespiratory arrest. Other reports noted levels up to 1210 ng/mL, with and frequently observed, supporting N-ethylpentylone's contribution via serotonin and release leading to sympathomimetic toxicity. Incidence trends aligned with market emergence, peaking in 2017–2018 as N-ethylpentylone proliferated in ecstasy-like products, correlating with DEA National Forensic Laboratory Information System detections exceeding 60% positivity for the substance in submitted samples by late 2018. Temporary scheduling under the in August 2018 contributed to a decline in pure-form encounters, though persistence occurred through 2020 in adulterated street drugs, with attributing deaths via blood levels above 100 ng/mL indicating lethality in mono-intoxication scenarios. Post-2020 data remain sparse, but forensic trends suggest reduced standalone fatalities amid broader synthetic stimulant adulteration patterns.

United States Regulation

The (DEA) temporarily placed N-ethylpentylone into Schedule I of the (CSA) on August 31, 2018, pursuant to emergency scheduling authority under 21 U.S.C. § 811(h), determining it posed an imminent hazard to public safety due to documented abuse, overdose deaths, and its structural similarity to other Schedule I synthetic cathinones like MDPV and . This temporary control, effective until August 31, 2020, prohibited manufacture, distribution, possession, and importation except for authorized research, reflecting findings of high abuse potential evidenced by law enforcement seizures and forensic identifications in biological samples from fatalities. The temporary scheduling was extended for one year on August 27, 2020, to August 31, 2021, allowing completion of permanent scheduling proceedings amid ongoing evidence of illicit distribution and health risks. Permanent placement in Schedule I was finalized via a rule published in the on June 14, 2021, effective that date, after a notice-and-comment period confirming N-ethylpentylone satisfies CSA criteria under 21 U.S.C. § 812(b)(1): (1) high potential for abuse, comparable to Schedule I stimulants based on user reports of euphoria, increased energy, and empathy akin to ; (2) no currently accepted medical use in the United States, lacking FDA approval or status; and (3) absence of accepted safety for use under medical supervision, given risks of severe agitation, cardiovascular toxicity, and death observed in case data. Prior to federal temporary scheduling, N-ethylpentylone was not explicitly listed under the CSA but faced variable state-level restrictions; for instance, in , it could be prosecuted as a controlled dangerous substance analog under § 5-207 if intended for consumption and substantially similar in structure and effect to Schedule I like , enabling enforcement against distribution despite lacking specific naming in state schedules. Other states with broad synthetic bans or analog provisions similarly addressed it pre-2018, though federal action standardized nationwide prohibition.

International Controls

N-Ethylpentylone is monitored globally as a new psychoactive substance (NPS) by the United Nations Office on Drugs and Crime (UNODC) through its Early Warning Advisory on NPS, which tracks detections, risks, and trends to inform member states. However, it has not been scheduled under the 1961 , the 1971 , or the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, leaving international control reliant on national implementations rather than binding treaty obligations. In , synthetic cathinones like N-ethylpentylone are subject to varying national controls, with several member states adopting generic bans on substituted cathinones following early detections around 2005–2010, capturing structural analogs under broad definitions to address rapidly evolving NPS. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) supports risk assessments that have prompted specific listings or analog provisions in countries such as (under the New Psychoactive Substances Act) and others, though enforcement varies due to differences in legislative scopes. In the , N-ethylpentylone is prohibited under the , which criminalizes the production, supply, offer to supply, and possession with intent to supply any psychoactive substance intended for human consumption, excluding specific exemptions like medicines. has controlled it as a Schedule I substance under the since May 2017, aligning with efforts to restrict synthetic cathinones amid rising detections. In , it is classified as a prohibited substance under federal and state legislation, with frequent seizures reported in border and domestic operations, including admixtures in and ecstasy mimics. Global disparities in scheduling persist, as not all nations have enacted specific or generic bans, enabling synthesis and from regions with lax regulations, such as certain Asian manufacturing hubs, which complicates international enforcement and contributes to cross-border trafficking challenges.

Societal Impact

Recreational Use Patterns

N-Ethylpentylone has been documented in recreational contexts primarily as a substitute for (ecstasy) within (EDM) festivals and scenes, where users seek similar stimulant and euphoric effects. Surveillance data from services and seizures indicate its distribution in pressed pills mimicking ecstasy tablets, often without user awareness of the substitution. Encounters with the substance in the U.S. illicit market rose dramatically from its identification in 2014 through 2018, reflecting its integration into party drug supply chains. Typical recreational doses range from 100-200 mg orally, aligned with common consumption levels, though this can lead to unintended overdose due to N-ethylpentylone's differing potency and . Users often obtain the substance online from research chemical vendors marketing it as a novel psychoactive substance or through street-level sales misrepresented as ecstasy. Demographic patterns mirror those of and other synthetic cathinones, with primary users being youths and young adults aged 18-35 frequenting and environments. High adulteration rates contribute to misdosing risks; for instance, analyses of seized ecstasy samples in various markets showed N-ethylpentylone present in up to 12% of cases starting around 2016, with U.S. forensic data from 2018-2020 highlighting its frequent substitution in presumed products.

Debates on Prohibition and Harm Reduction

The U.S. (DEA) has advocated for Schedule I classification of N-ethylpentylone, citing its high potential for abuse, lack of accepted medical use, and association with severe health risks, including stimulant effects akin to that can induce , , and cardiovascular complications. Proponents of emphasize of harm, such as the drug's linkage to at least 151 overdose deaths since 2015, often involving but with N-ethylpentylone as a key factor in fatalities exhibiting blood concentrations from 170 to 1300 ng/mL. This scheduling, implemented temporarily in 2018 and finalized in 2021, aims to deter recreational use by imposing strict penalties, mirroring controls on analogs that have reduced certain market availabilities despite the emergence of structural variants. Critics of stringent argue that Schedule I designation exacerbates dynamics, fostering adulteration and unpredictable purity levels as clandestine producers substitute or mix synthetic cathinones like N-ethylpentylone into misrepresented products such as or counterfeit pharmaceuticals, thereby heightening overdose risks from unknown dosing. For instance, analyses of illicit supplies have revealed N-ethylpentylone contaminating ecstasy tablets and Xanax bars, complicating user harm assessment and contributing to unintended exposures without evidence that scheduling alone curtails overall NPS innovation or trafficking. Such underground adaptations, observed in synthetic cathinone markets post-scheduling waves, underscore causal risks of driving compositional opacity rather than elimination, as producers evade controls via minor chemical tweaks. Harm reduction perspectives prioritize non-legalization strategies like kits and pill-checking services, which have successfully identified N-ethylpentylone in festival samples mislabeled as and in adulterated opioids, enabling users to discard high-risk batches and averting potential acute toxicities without endorsing consumption. Pilot programs, such as those detecting N-ethylpentylone at concentrations up to 919 mg in seized pills, demonstrate these tools' utility in real-time risk mitigation, correlating with reduced event-related medical interventions for NPS exposures. These approaches address immediate dangers like or cardiovascular events from impure stimulants, contrasting with prohibition's focus on supply suppression, though their efficacy remains debated amid polysubstance contexts where N-ethylpentylone deaths typically involve co-ingestants. Debates balance N-ethylpentylone's absence of therapeutic value against individual autonomy claims, weighing societal burdens like presentations for synthetic intoxications—often involving agitation, seizures, and renal injury—against the disproportionate harms of legal substances, where alcohol accounts for approximately 88,000 annual U.S. deaths and over 480,000, dwarfing NPS fatalities. While prohibitionists highlight deterrence from documented cases, skeptics caution against inflating NPS threats as an "epidemic" without contextualizing low per-capita incidence relative to entrenched legal drugs, advocating evidence-based that incorporates testing data to minimize adulteration-driven casualties over blanket .

References

  1. https://www.deadiversion.usdoj.gov/drug_chem_info/n-ethylpentylone.pdf
  2. https://onlinelibrary.wiley.com/doi/10.1111/adb.12755
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197033/
  4. https://pubmed.ncbi.nlm.nih.gov/30207090/
  5. https://pubmed.ncbi.nlm.nih.gov/30356999/
  6. https://pubmed.ncbi.nlm.nih.gov/30985062/
  7. https://www.federalregister.gov/documents/2021/06/14/2021-12261/schedules-of-controlled-substances-placement-of-n-ethylpentylone-in-schedule-i
  8. https://pubmed.ncbi.nlm.nih.gov/30198687/
  9. https://pubmed.ncbi.nlm.nih.gov/31033523/
  10. https://pubmed.ncbi.nlm.nih.gov/34816436/
  11. https://pubmed.ncbi.nlm.nih.gov/33305793/
  12. https://pubchem.ncbi.nlm.nih.gov/compound/N-Ethylpentylone
  13. https://downloads.regulations.gov/DEA-2020-0025-0002/content.pdf
  14. https://www.swgdrug.org/Monographs/N-Ethylpentylone.pdf
  15. https://www.sciencedirect.com/science/article/abs/pii/S2468170924000031
  16. https://www.unodc.org/documents/scientific/Recommended_methods_for_the_Identification_and_Analysis_of_Synthetic_Cathinones_in_Seized_Materials-Rev..pdf
  17. https://cdn.who.int/media/docs/default-source/46th-ecdd/dipentylone_46th-ecdd_critical-review_public-version.pdf
  18. https://d-nb.info/119552773X/34
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC2968086/
  20. https://researchonline.ljmu.ac.uk/id/eprint/9577/1/N-Ethylnorpentylone.pdf
  21. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/dta.2502
  22. https://pubmed.ncbi.nlm.nih.gov/29618077/
  23. https://www.researchgate.net/publication/332419181_Pharmacokinetics_of_N-ethylpentylone_and_its_effect_on_increasing_levels_of_dopamine_and_serotonin_in_the_nucleus_accumbens_of_conscious_rats
  24. https://www.mdpi.com/1424-8247/18/5/721
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC7316160/
  26. https://researchonline.ljmu.ac.uk/id/eprint/9577/
  27. https://www.federalregister.gov/documents/2018/08/31/2018-18988/schedules-of-controlled-substances-temporary-placement-of-n-ethylpentylone-in-schedule-i
  28. https://www.regulations.gov/document/DEA-2020-0025-0001
  29. https://academic.oup.com/jat/article/42/7/467/4957061
  30. https://www.federalregister.gov/documents/2020/08/27/2020-19007/schedules-of-controlled-substances-placement-of-n-ethylpentylone-in-schedule-i
  31. https://onlinelibrary.wiley.com/doi/10.1111/jnc.15542
  32. https://pubs.acs.org/doi/10.1021/acsptsci.4c00299
  33. https://knowyourstuff.nz/this-summers-crap-drug-n-ethylpentylone/
  34. https://drugfoundation.org.nz/news-and-reports/you-think-its-mdma-but-is-it
  35. https://hi-ground.org/substances/cathinones/
  36. https://www.dea.gov/press-releases/2018/08/31/dea-acts-against-dangerous-deadly-designer-synthetic-drug-linked-151
  37. https://link.springer.com/article/10.1007/s11419-019-00483-0
  38. https://www.tandfonline.com/doi/abs/10.1080/15563650.2021.1909730
  39. https://www.health.vic.gov.au/drug-alerts/n-ethylpentylone-in-cocaine
  40. https://www.health.vic.gov.au/drug-alerts/green-ups-pills-containing-n-ethylpentylone-no-mdma
  41. https://link.springer.com/article/10.1007/s00213-022-06173-x
  42. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16506
  43. https://www.soft-tox.org/assets/NPSLiterature/ethylpent.pdf
  44. https://academic.oup.com/jat/article/41/4/342/2964655
  45. https://www.sciencedirect.com/science/article/pii/S0379073824002858
  46. https://www.sciencedirect.com/science/article/abs/pii/S0376871619300961
  47. https://www.tandfonline.com/doi/full/10.4161/23328940.2014.985953
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC9640761/
  49. https://www.dea.gov/sites/default/files/2020-02/DIR-007-20%25202019%2520National%2520Drug%2520Threat%2520Assessment%2520-%2520low%2520res210.pdf
  50. https://www.federalregister.gov/documents/2020/08/27/2020-19011/schedules-of-controlled-substances-extension-of-temporary-placement-of-n-ethylpentylone-in-schedule
  51. https://www.unodc.org/documents/commissions/CND/Scheduling_Resource_Material/Scheduling_Control_Regimes.pdf
  52. https://www.euda.europa.eu/publications/drug-profiles/synthetic-cathinones_en
  53. https://www.euda.europa.eu/topics/pods/synthetic-cathinones-injection_en
  54. https://pubs.acs.org/doi/10.1021/acs.estlett.1c00807
  55. https://academic.oup.com/jat/article/42/8/544/5145131
  56. https://www.researchgate.net/publication/327595116_Full_Title_Analytical_quantification_intoxication_case_series_and_pharmacological_mechanism_of_action_for_N-ethylnorpentylone_N-ethylpentylone_or_ephylone
  57. https://journals.sagepub.com/doi/10.1177/20503245221099209
  58. https://www.researchgate.net/publication/328368237_Synthetic_cathinone_adulteration_of_illegal_drugs
  59. https://dancesafe.org/testit-alert-yellow-counterfeit-xanax-bar-tests-as-4-chloro-alpha-pvp-and-n-ethylpentylone-both-cathinones/
  60. https://pubmed.ncbi.nlm.nih.gov/30969348/
  61. https://www.harmreductionaustralia.org.au/wp-content/uploads/2018/06/Pill-Testing-Pilot-ACT-June-2018-Final-Report.pdf
  62. https://www.gov.uk/government/publications/synthetic-cathinones-an-updated-harms-assessment/synthetic-cathinones-an-updated-harms-assessment-accessible
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.